X

Trial Profile

A proof of concept trial of Epinephrine Sublingual Soluble Film for the treatment of anaphylaxis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Mar 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AQST 108 (Primary)
Indications Anaphylaxis
Focus Proof of concept; Therapeutic Use
Sponsors Aquestive Therapeutics

Most Recent Events

25 Mar 2021 According to an Aquestive Therapeutics media release, the company plans on meeting with the FDA in the second half of 2021 to review these results and discuss next steps in the development of AQST-108.
25 Mar 2021 According to an Aquestive Therapeutics media release, data from this trial will be presented in R&D event.
25 Mar 2021 Results published in an Aquestive Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com